AbbVie Goes Boldly Into Immuno-Neurology With Alector

AbbVie agreed to pay $205m up front to biotech start-up Alector to research a portfolio of antibody targets to treat Alzheimer's and other neurodegenerative diseases by harnessing the immune system.

Human brain illustrated with millions of small nerves - Conceptual 3d render

Now that the potential for harnessing the immune system to attack cancer has been well validated, drug makers are looking to the next big therapy area in which to explore the power of the immune system. One area that is getting attention, based on encouraging preclinical data, is neurodegenerative disease.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business